Daniel T. Michaeli

Heidelberg, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

The Healthcare Workforce Shortage of Nurses and Physicians: Practice, Theory, Evidence, and Ways Forward.

The Healthcare Workforce Shortage of Nurses and Physicians: Practice, Theory, Evidence, and Ways Forward.

Journal: Policy, politics & nursing practice

Published: October 13, 2024

Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs.

Value-Based Indication-Specific Pricing and Weighted-Average Pricing: Estimated Price and Cost Savings for Cancer Drugs.

Journal: PharmacoEconomics

Published: October 13, 2024

Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs.

Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs.

Journal: Targeted oncology

Published: June 28, 2024

Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications.

Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications.

Journal: BMJ evidence-based medicine

Published: April 30, 2024

Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price.

Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price.

Journal: Breast cancer (Tokyo, Japan)

Published: February 25, 2024

Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition.

Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition.

Journal: PharmacoEconomics

Published: September 25, 2023

Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price.

Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: September 20, 2023

Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending.

Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: September 06, 2023

Clinical benefit, development, innovation, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations.

Clinical benefit, development, innovation, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations.

Journal: Journal of the National Cancer Institute

Published: August 07, 2023

Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.

Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.

Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions

Published: July 02, 2023

Gene regulation for inflammation and inflammation resolution differs between umbilical arterial and venous endothelial cells.

Gene regulation for inflammation and inflammation resolution differs between umbilical arterial and venous endothelial cells.

Journal: Scientific reports

Published: May 27, 2023

Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.

Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.

Journal: The European journal of health economics : HEPAC : health economics in prevention and care

Published: May 19, 2023

Showing 1-12 of 30

Last Updated: 09/26/2026